# Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

> **NCT03792256** · PHASE1 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 12 (actual)

## Conditions studied

- Leukemia, Lymphocytic
- Lymphoblastic Lymphoma
- T-cell Lymphoma
- T-cell Leukemia
- Recurrent Disease
- Acute Leukemia

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Hydrocortisone
- **DRUG:** Doxorubicin
- **DRUG:** Prednisolone
- **DRUG:** Vincristine
- **DRUG:** Pegaspargase
- **DRUG:** Hydrocortisone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03792256
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-11
- **Primary completion:** 2021-06-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03792256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03792256, "Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03792256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*